Strong Pharma-led momentum supports FY27 growth, but Q4 included a material non-recurring tariff benefit.
| Quarter | Q4 FY26 |
|---|---|
| Call date | 2026-08-11 |
| Length | 61 minutes |
| EPS | $2.91 |
| EPS consensus | $2.42 |
| Revenue | $65.6B |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q1 FY26 · Q4 FY25 · Q3 FY25 · Q2 FY25 · Q1 FY25 · Q2 FY22
All CAH earnings · Back to CAH overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.